

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssseptal203pxs



PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	6	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	11	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	14	JUL 28	STN Viewer performance improved
NEWS	15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	16	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	18	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	21	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	23	SEP 29	IFICLS enhanced with new super search field
NEWS	24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	27	OCT 07	Multiple databases enhanced for more flexible patent number searching





```

chain nodes :
10 17 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 18 19 20 21 22 23
chain bonds :
1-11 5-18 8-10 12-17 21-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
2-7 3-9 5-18 7-8 8-9 18-19 18-23 19-20 20-21 21-22 22-23
exact bonds :
1-11 8-10 12-17 21-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 exa

SAMPLE SEARCH INITIATED 14:23:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA EXA SAM L1

=> s l1 ful

FULL SEARCH INITIATED 14:23:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 307 TO ITERATE

100.0% PROCESSED 307 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1

=> d l3 1-4


L3 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN

RN 476148-82-0 REGISTRY

ED Entered STN: 13 Dec 2002

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,

hydrochloride, hydrate (1:1:1) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
monohydrochloride, monohydrate (9CI)  
MF C17 H17 F N4 S . Cl H . H2 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL  
CRN (99487-25-9)




● HCl

● H2O

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L3 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 109348-38-1 REGISTRY  
ED Entered STN: 25 Jul 1987  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:?) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (9CI)  
MF C17 H17 F N4 S . x Cl H  
SR CA  
LC STN Files: BIOTECHNO, CA, CAPLUS, EMBASE, PROUSDDR, SYNTHLINE  
CRN (99487-25-9)



● x HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 99487-26-0 REGISTRY  
ED Entered STN: 21 Dec 1985  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
monohydrochloride (9CI)  
OTHER NAMES:  
CN MCI 225  
DR 135991-48-9  
MF C17 H17 F N4 S . Cl H  
SR CA  
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN,  
EMBASE, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR,  
RIECS\*, SCISEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
CRN (99487-25-9)




● HCl

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 99487-25-9 REGISTRY  
ED Entered STN: 21 Dec 1985  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)  
MF C17 H17 F N4 S  
CI COM  
SR CA  
LC STN Files: BIOTECHNO, CA, CAPLUS, CHEMCATS, EMBASE, PHAR, PROUDDR,  
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file uspatfull  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 186.36 186.57

FILE 'USPATFULL' ENTERED AT 14:23:31 ON 07 OCT 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 7 Oct 2008 (20081007/PD)  
FILE LAST UPDATED: 7 Oct 2008 (20081007/ED)  
HIGHEST GRANTED PATENT NUMBER: US7434267  
HIGHEST APPLICATION PUBLICATION NUMBER: US20080244796  
CA INDEXING IS CURRENT THROUGH 7 Oct 2008 (20081007/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 7 Oct 2008 (20081007/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2008  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2008

USPATFULL now includes complete International Patent Classification (IPC)  
reclassification data for the second quarter of 2008.

=> s l3  
L4 39 L3  
  
=> s l4 and cancer  
150861 CANCER  
L5 22 L4 AND CANCER  
  
=> d l5 1-22 ibib, abs, hitstr

L5 ANSWER 1 OF 22 USPATFULL on STN  
 ACCESSION NUMBER: 2008:214787 USPATFULL  
 TITLE: Modulation of Neurogenesis with Biguanides and GSK3-beta Agents  
 INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
 Carter, Todd, San Diego, CA, UNITED STATES  
 Morse, Andrew, San Diego, CA, UNITED STATES  
 Treuner, Kai, San Diego, CA, UNITED STATES  
 Lorrain, Kym I., San Diego, CA, UNITED STATES  
 PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080188457	A1	20080807
APPLICATION INFO.:	US 2008-24923	A1	20080201 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-888030P	20070202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	4365	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of one or more biguanides in combination with one or more GSK3- $\beta$  agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 22 USPATFULL on STN  
 ACCESSION NUMBER: 2008:196095 USPATFULL  
 TITLE: Modulation Of Neurogenesis With Use of Modafinil  
 INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
 Carter, Todd A., San Diego, CA, UNITED STATES  
 Morse, Andrew, San Diego, CA, UNITED STATES  
 Treuner, Kai, San Diego, CA, UNITED STATES  
 Lorrain, Kym I., San Diego, CA, UNITED STATES  
 PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080171750	A1	20080717
APPLICATION INFO.:	US 2008-972467	A1	20080110 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-884584P	20070111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	



NUMBER OF CLAIMS: 40  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Page(s)  
LINE COUNT: 4561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of modafinil, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 22 USPATFULL on SIN

ACCESSION NUMBER: 2008:190961 USPATFULL  
TITLE: Modulation of Neurogenesis By Melatonineric Agents  
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
Redwine, Jeff, San Diego, CA, UNITED STATES  
Hoffmaster, Christine, El Cajon, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc, San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080167363	A1	20080710
APPLICATION INFO.:	US 2007-965110	A1	20071227 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-882434P	20061228 (60)
	US 2006-882440P	20061228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	

NUMBER OF CLAIMS: 51  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 13 Drawing Page(s)  
LINE COUNT: 4901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other melatonineric agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 22 USPATFULL on SIN

ACCESSION NUMBER: 2008:190889 USPATFULL  
TITLE: NEUROGENESIS BY MODULATING ANGIOTENSIN  
INVENTOR(S): Barlow, Carolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080167291	A1	20080710
APPLICATION INFO.:	US 2007-746539	A1	20070509 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-746859P	20060509 (60)
	US 2006-807594P	20060717 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	5191	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 22 USPATFULL on SIN

ACCESSION NUMBER:	2008:175983 USPATFULL
TITLE:	COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION
INVENTOR(S):	Lange, Josephus H.M., Weesp, NETHERLANDS Kruse, Cornelis G., Weesp, NETHERLANDS Shadid, Belal, Weesp, NETHERLANDS
PATENT ASSIGNEE(S):	Solvay Pharmaceuticals B.V. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080153867	A1	20080626
APPLICATION INFO.:	US 2007-957948	A1	20071217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-875808P	20061220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1612	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Embodiments of this invention relate to compounds having a combination of cannabinoid-CB <sub>1</sub> antagonist and cholinesterase inhibition, to pharmaceutical compositions comprising these compounds, to methods for preparing these compounds, methods for preparing novel intermediates useful for the synthesis of these compounds, and methods for preparing compositions comprising these compounds. The invention also relates to methods of treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction or substance abuse by administering a	

pharmaceutical composition comprising these compounds to a patient in need thereof. A compound with a combination of cannabinoid-CB<sub>1</sub> antagonistism and cholinesterase inhibition is a compound of formula (1)

##STR1##

wherein the symbols have the meanings given in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99487-26-0DP, MCI-225, pharmacophoric element, conjugates with

CB<sub>1</sub> antagonist pharmacophoric element

(preparation of compds. with both CB<sub>1</sub> receptor antagonistic and acetylcholinesterase inhibiting activities)

RN 99487-26-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 6 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2008:124776 USPATFULL

TITLE: MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS

INVENTOR(S): Barlow, Carolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080108574	A1	20080508
APPLICATION INFO.:	US 2007-862115	A1	20070926 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-827202P	20060927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	

LINE COUNT: 5671

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a melanocortin receptor (MCR) modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2008:118467 USPATFULL  
TITLE: PPAR MEDIATED MODULATION OF NEUROGENESIS  
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080103165	A1	20080501
APPLICATION INFO.:	US 2007-857221	A1	20070918 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-826206P	20060919 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	5050	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2008:118408 USPATFULL  
TITLE: HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS  
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
Redwine, Jeff, San Diego, CA, UNITED STATES  
Hoffmaster, Christine, Lakeside, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080103105	A1	20080501
APPLICATION INFO.:	US 2007-858790	A1	20070920 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-826710P	20060922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	5234	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of an HMGR modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2008:73637 USPATFULL

TITLE: COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE

INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080064671	A1	20080313
APPLICATION INFO.:	US 2007-766721	A1	20070621 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-825080P	20060908 (60)
	US 2006-868510P	20061204 (60)
	US 2007-884584P	20070111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	4635	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system.

The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 22 USPATFULL on STN  
ACCESSION NUMBER: 2007:309347 USPATFULL  
TITLE: 5 HT RECEPTOR MEDIATED NEUROGENESIS  
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Todd, San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070270449	A1	20071122
APPLICATION INFO.:	US 2007-746008	A1	20070508 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-746878P	20060509 (60)
	US 2006-805436P	20060621 (60)
	US 2006-882429P	20061228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	53 Drawing Page(s)	
LINE COUNT:	5284	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 22 USPATFULL on STN  
ACCESSION NUMBER: 2007:291200 USPATFULL  
TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives  
INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM  
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM  
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788565P	20060331 (60)
	US 2006-808905P	20060526 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE,  
BOSTON, MA, 02109-2127, US


NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)  
LINE COUNT: 2940

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0, MCI-225  
(soluble salts of thienopyrimidine derivs., and therapeutic use)  
RN 99487-26-0 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 99487-25-9D, salts  
(soluble salts of thienopyrimidine derivs., and therapeutic use)  
RN 99487-25-9 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



IT 99487-25-9  
(soluble salts of thienopyrimidine derivs., and therapeutic use)  
RN 99487-25-9 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-

(CA INDEX NAME)



L5 ANSWER 12 OF 22 USPATFULL on STN  
ACCESSION NUMBER: 2007:291192 USPATFULL  
TITLE: Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine  
INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM  
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM  
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254891	A1	2007/1101
APPLICATION INFO.:	US 2007-728947	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788338P	20060331 (60)
	US 2006-808603P	20060526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	

NUMBER OF CLAIMS: 33  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 11 Drawing Page(s)  
LINE COUNT: 3877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9D, salts 99487-26-0, MCI-225  
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)

RN 99487-25-9 USPATFULL


CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)





RN 99487-26-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L5 ANSWER 13 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2007:278709 USPATFULL

TITLE: MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS

INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES

Carter, Todd A., San Diego, CA, UNITED STATES

Morse, Andrew, San Diego, CA, UNITED STATES

Treuner, Kai, San Diego, CA, UNITED STATES

Lorrain, Kym I., San Diego, CA, UNITED STATES

Gitnick, Dana, San Marcos, CA, UNITED STATES

Pires, Jammieson C., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc, San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070244143	A1	20071018
APPLICATION INFO.:	US 2007-683982	A1	20070308 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-805440P	20060621 (60)
	US 2006-780415P	20060308 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 9 Drawing Page(s)

LINE COUNT: 4135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2007:237654 USPATFULL

TITLE: MODULATION OF NEUROGENESIS BY PDE INHIBITION

INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES

Carter, Todd A., San Diego, CA, UNITED STATES

Lorrain, Kym I., San Diego, CA, UNITED STATES

Pires, Jammieson C., San Diego, CA, UNITED STATES

Treuner, Kai, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070208029	A1	20070906
APPLICATION INFO.:	US 2006-551667	A1	20061020 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-729366P	20051021 (60)
	US 2006-784605P	20060321 (60)
	US 2006-807594P	20060717 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US

NUMBER OF CLAIMS: 26

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 4538

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2007:128661 USPATFULL

TITLE: GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS

INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES

Carter, Todd A., San Diego, CA, UNITED STATES

Morse, Andrew, San Diego, CA, UNITED STATES

Lorrain, Kym I., San Diego, CA, UNITED STATES

Pires, Jammieson C., San Diego, CA, UNITED STATES

Treuner, Kai, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070112017	A1	20070517
APPLICATION INFO.:	US 2006-554315	A1	20061030 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-731947P	20051031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	4793	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2007:89508 USPATFULL

TITLE: MODULATION OF NEUROGENESIS BY HDac INHIBITION

INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Todd A., San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
Pires, Jammieson C., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Gitnick, Dana, San Marcos, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Dearie, Alejandro R., Chula Vista, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070078083	A1	20070405
APPLICATION INFO.:	US 2006-470957	A1	20060907 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-715219P	20050907 (60)
	US 2006-764963P	20060203 (60)
	US 2006-785713P	20060324 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	5466	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating

or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2007:56630 USPATFULL  
TITLE: NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION  
INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
Carter, Tood A., San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
Pires, Jammieson C., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Gitnick, Dana, San Marcos, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Broadhead, Alex, San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070049576	A1	20070301
APPLICATION INFO.:	US 2006-467527	A1	20060825 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-711846P	20050826 (60)
	US 2005-727127P	20051014 (60)
	US 2005-738133P	20051117 (60)
	US 2006-803826P	20060602 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US  
NUMBER OF CLAIMS: 26  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 15 Drawing Page(s)  
LINE COUNT: 4031

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2006:341526 USPATFULL  
TITLE: Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors  
INVENTOR(S): Thor, Karl Bruce, Cary, NC, UNITED STATES  
Ricca, Daniel J., Rougemont, NC, UNITED STATES  
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 20060293309 A1 20061228  
 APPLICATION INFO.: US 2006-389887 A1 20060327 (11)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-666253P	20050328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	101	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4659	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention features compounds, for example, 5-HT.sub.3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT.sub.3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT.sub.3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT.sub.3 receptors can be lessened or reduced using the peripherally restricted compounds of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.  
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)  
 RN 99487-26-0 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9  
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)




L5 ANSWER 19 OF 22 USPATFULL on STN  
 ACCESSION NUMBER: 2006:196249 USPATFULL  
 TITLE: New therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine  
 INVENTOR(S): Cavalla, David, Cambridge, UNITED KINGDOM  
 Gristwood, Robert William, Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060167005	A1	20060727
APPLICATION INFO.:	US 2003-525532	A1	20030828 (10)
	WO 2003-GB3720		20030828
			20050725 PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-20064	20020829
	GB 2003-16115	20030709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1-15	
LINE COUNT:	225	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	(4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 99487-25-9 476148-82-0  
 (therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



RN 476148-82-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H<sub>2</sub>O

L5 ANSWER 20 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2004:321517 USPATFULL

TITLE: Method of treating nausea, vomiting, retching or any combination thereof

INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES

Miller, Cheryl L., Natick, MA, UNITED STATES

Thor, Karl B., Morrisville, NC, UNITED STATES

PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254172	A1	20041216
	US 7094786	B2	20060822
APPLICATION INFO.:	US 2004-846979	A1	20040514 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	


LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017  
NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: CLM-01-70  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 1783

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>3</sub> receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts  
(method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)  
RN 99487-25-9 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 99487-25-9 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



L5 ANSWER 21 OF 22 USPATFULL on STN  
ACCESSION NUMBER: 2004:321516 USPATFULL  
TITLE: Method of treating nausea, vomiting, retching or any combination thereof  
INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
Miller, Cheryl L., Natick, MA, UNITED STATES



PATENT ASSIGNEE(S): Thor, Karl B., Morrisville, NC, UNITED STATES  
Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254171	A1	20041216
APPLICATION INFO.:	US 2004-846978	A1	20040514 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING		


	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	89	
EXEMPLARY CLAIM:	CLM-01-70	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1991	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts  
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)  
RN 99487-25-9 USPTFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 99487-25-9 USPTFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



L5 ANSWER 22 OF 22 USPATFULL on STN  
 ACCESSION NUMBER: 2004:190737 USPATFULL  
 TITLE: Method of treating nausea, vomiting, retching or any combination thereof  
 INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
 Miller, Cheryl L., Natick, MA, UNITED STATES  
 Thor, Karl B., Morrisville, NC, UNITED STATES  
 PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040147510	A1	20040729
APPLICATION INFO.:	US 2004-757981	A1	20040113 (10)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	70	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	2041	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>3</sub> receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts  
 (method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:22:34 ON 07 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:22:41 ON 07 OCT 2008

L1 STRUCTURE UPLOADED  
 L2 0 S L1 EXA  
 L3 4 S L1 FUL

FILE 'USPATFULL' ENTERED AT 14:23:31 ON 07 OCT 2008

L4 39 S L3  
 L5 22 S L4 AND CANCER

=> s l3 and chemotherapy

39 L3  
 46084 CHEMOTHERAPY  
 L6 21 L3 AND CHEMOTHERAPY

=> s l3 and chemotherapeutic

39 L3  
 35633 CHEMOTHERAPEUTIC  
 L7 7 L3 AND CHEMOTHERAPEUTIC

=> d l7 1-7 ibib, abs, hitstr

L7 ANSWER 1 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2007:291200 USPATFULL  
 TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives  
 INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM  
 Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM  
 PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED  
 STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788565P	20060331 (60)
	US 2006-808905P	20060526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2940	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0, MCI-225

(soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-26-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 99487-25-9D, salts

(soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)




IT 99487-25-9

(soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



L7 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2007:291192 USPATFULL

TITLE: Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine

INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM  
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254891	A1	20071101
APPLICATION INFO.:	US 2007-728947	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788338P	20060331 (60)
	US 2006-808603P	20060526 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE,  
BOSTON, MA, 02109-2127, US

NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Page(s)

LINE COUNT: 3877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present

invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9D, salts 99487-26-0, MCI-225

(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)


RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 99487-26-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

L7 ANSWER 3 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2007:89508 USPATFULL

TITLE: MODULATION OF NEUROGENESIS BY HDac INHIBITION

INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES

Carter, Todd A., San Diego, CA, UNITED STATES

Lorrain, Kym I., San Diego, CA, UNITED STATES

Pires, Jammieson C., San Diego, CA, UNITED STATES

Morse, Andrew, San Diego, CA, UNITED STATES

Gitnick, Dana, San Marcos, CA, UNITED STATES

Treuner, Kai, San Diego, CA, UNITED STATES

Dearie, Alejandro R., Chula Vista, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----

PATENT INFORMATION: US 20070078083 A1 20070405  
APPLICATION INFO.: US 2006-470957 A1 20060907 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-715219P	20050907 (60)
	US 2006-764963P	20060203 (60)
	US 2006-785713P	20060324 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	5466	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L7 ANSWER 4 OF 7 USPATFULL on STN  
ACCESSION NUMBER: 2006:341526 USPATFULL  
TITLE: Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors  
INVENTOR(S): Thor, Karl Bruce, Cary, NC, UNITED STATES  
Ricca, Daniel J., Rougemont, NC, UNITED STATES  
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060293309	A1	20061228
APPLICATION INFO.:	US 2006-389887	A1	20060327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-666253P	20050328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	101	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4659	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The instant invention features compounds, for example, 5-HT.sub.3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT.sub.3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT.sub.3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT.sub.3 receptors can be lessened or reduced using the peripherally restricted compounds of the invention.	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.  
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3  
 antagonists for treatment of disorders and conditions)  
 RN 99487-26-0 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9  
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3  
 antagonists for treatment of disorders and conditions)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



L7 ANSWER 5 OF 7 USPATFULL on STN  
 ACCESSION NUMBER: 2004:321517 USPATFULL  
 TITLE: Method of treating nausea, vomiting, retching or any  
 combination thereof  
 INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
 Miller, Cheryl L., Natick, MA, UNITED STATES  
 Thor, Karl B., Morrisville, NC, UNITED STATES  
 PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254172	A1	20041216
	US 7094786	B2	20060822
APPLICATION INFO.:	US 2004-846979	A1	20040514 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING		

NUMBER

DATE




PRIORITY INFORMATION: US 2003-492478P 20030804 (60)  
 US 2003-440076P 20030113 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017  
 NUMBER OF CLAIMS: 7  
 EXEMPLARY CLAIM: CLM-01-70  
 NUMBER OF DRAWINGS: 3 Drawing Page(s)  
 LINE COUNT: 1783  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT.sub.3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT.sub.3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts  
 (method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



ACCESSION NUMBER: 2004:321516 USPATFULL  
 TITLE: Method of treating nausea, vomiting, retching or any combination thereof  
 INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
 Miller, Cheryl L., Natick, MA, UNITED STATES  
 Thor, Karl B., Morrisville, NC, UNITED STATES  
 PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254171	A1	20041216
APPLICATION INFO.:	US 2004-846978	A1	20040514 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING		


	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	89	
EXEMPLARY CLAIM:	CLM-01-70	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1991	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>3</sub> receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts  
 (method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-

(CA INDEX NAME)



L7 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:190737 USPATFULL

TITLE: Method of treating nausea, vomiting, retching or any combination thereof

INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
Miller, Cheryl L., Natick, MA, UNITED STATES  
Thor, Karl B., Morrisville, NC, UNITED STATES

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040147510	A1	20040729
APPLICATION INFO.:	US 2004-757981	A1	20040113 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	70	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	2041	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>3</sub> receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99487-25-9 99487-25-9D, salts

(method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 USPATFULL


CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-

(CA INDEX NAME)



RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



=> s l3 and (nausea or vomit? or emesis)

39 L3

16816 NAUSEA

14017 VOMIT?

3851 EMESIS

L8 15 L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=> d l8 1-15 ibib, abs, hitstr

L8 ANSWER 1 OF 15 USPATFULL on SIN

ACCESSION NUMBER: 2008:190889 USPATFULL

TITLE: NEUROGENESIS BY MODULATING ANGIOTENSIN

INVENTOR(S): Barlow, Carolee, Del Mar, CA, UNITED STATES

Carter, Todd A., San Diego, CA, UNITED STATES

Treuner, Kai, San Diego, CA, UNITED STATES

Lorrain, Kym I., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080167291	A1	20080710
APPLICATION INFO.:	US 2007-746539	A1	20070509 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-746859P	20060509 (60)
	US 2006-807594P	20060717 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO  
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US  
NUMBER OF CLAIMS: 40  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 17 Drawing Page(s)  
LINE COUNT: 5191

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and  
conditions of the central and peripheral nervous system by stimulating  
or increasing neurogenesis. The invention includes compositions and  
methods based on modulation angiotensin activity to stimulate or  
activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2008:175983 USPATFULL  
TITLE: COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1  
ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION  
INVENTOR(S): Lange, Josephus H.M., Weesp, NETHERLANDS  
Kruse, Cornelis G., Weesp, NETHERLANDS  
Shadid, Belal, Weesp, NETHERLANDS  
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080153867	A1	20080626
APPLICATION INFO.:	US 2007-957948	A1	20071217 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-875808P	20061220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1612	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Embodiments of this invention relate to compounds having a combination  
of cannabinoid-CB.sub.1 antagonism and cholinesterase inhibition, to  
pharmaceutical compositions comprising these compounds, to methods for  
preparing these compounds, methods for preparing novel intermediates  
useful for the synthesis of these compounds, and methods for preparing  
compositions comprising these compounds. The invention also relates to  
methods of treating Alzheimer's disease, cognitive disorders, memory  
disorders, dementia, attention deficit disorder, traumatic brain injury,  
drug dependence, addiction or substance abuse by administering a  
pharmaceutical composition comprising these compounds to a patient in  
need thereof. A compound with a combination of cannabinoid-CB.sub.1  
antagonism and cholinesterase inhibition is a compound of formula (1)


##STR1##

wherein the symbols have the meanings given in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-ODP, MCI-225, pharmacophoric element, conjugates with  
CB1 antagonist pharmacophoric element  
(preparation of compds. with both CB1 receptor antagonistic and  
acetylcholinesterase inhibiting activities)

RN 99487-26-0 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

L8 ANSWER 3 OF 15 USPATFULL on SIN  
ACCESSION NUMBER: 2007:291200 USPATFULL  
TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives  
INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM  
Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM  
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED  
STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254899	A1	20071101
APPLICATION INFO.:	US 2007-728966	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788565P	20060331 (60)
	US 2006-808905P	20060526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2940	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99487-26-0, MCI-225  
(soluble salts of thienopyrimidine derivs., and therapeutic use)

RN 99487-26-0 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 99487-25-9D, salts  
 (soluble salts of thienopyrimidine derivs., and therapeutic use)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



IT 99487-25-9  
 (soluble salts of thienopyrimidine derivs., and therapeutic use)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



L8 ANSWER 4 OF 15 USPATFULL on STN  
 ACCESSION NUMBER: 2007:291192 USPATFULL  
 TITLE: Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine  
 INVENTOR(S): Cooper, Martin Ian, Cambridgeshire, UNITED KINGDOM  
 Frampton, Christopher Stephen, Suffolk, UNITED KINGDOM  
 PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254891	A1	20071101
APPLICATION INFO.:	US 2007-728947	A1	20070327 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-788338P	20060331 (60)
	US 2006-808603P	20060526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3877	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		


AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9D, salts 99487-26-0, MCI-225  
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)

RN 99487-25-9 USPATFULL


CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 99487-26-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)





● HCl

L8 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:237654 USPATFULL  
 TITLE: MODULATION OF NEUROGENESIS BY PDE INHIBITION  
 INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
 Carter, Todd A., San Diego, CA, UNITED STATES  
 Lorrain, Kym I., San Diego, CA, UNITED STATES  
 Pires, Jammieson C., San Diego, CA, UNITED STATES  
 Treuner, Kai, San Diego, CA, UNITED STATES  
 PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070208029	A1	20070906
APPLICATION INFO.:	US 2006-551667	A1	20061020 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-729366P	20051021 (60)
	US 2006-784605P	20060321 (60)
	US 2006-807594P	20060717 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US  
 NUMBER OF CLAIMS: 26  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 6 Drawing Page(s)  
 LINE COUNT: 4538

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:128661 USPATFULL  
 TITLE: GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS  
 INVENTOR(S): Barlow, Carrolee, Del Mar, CA, UNITED STATES  
 Carter, Todd A., San Diego, CA, UNITED STATES

Morse, Andrew, San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
Pires, Jammieson C., San Diego, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
BrainCells, Inc., San Diego, CA, UNITED STATES (U.S.  
corporation)

PATENT ASSIGNEE(S):

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 20070112017	A1	20070517
APPLICATION INFO.:	US 2006-554315	A1	20061030 (11)

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2005-731947P	20051031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	4793	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 15 USPATFULL on STN  
ACCESSION NUMBER: 2007:56630 USPATFULL  
TITLE: NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION  
INVENTOR(S): Barlow, Carolee, Del Mar, CA, UNITED STATES  
Carter, Tood A., San Diego, CA, UNITED STATES  
Lorrain, Kym I., San Diego, CA, UNITED STATES  
Pires, Jammieson C., San Diego, CA, UNITED STATES  
Morse, Andrew, San Diego, CA, UNITED STATES  
Gitnick, Dana, San Marcos, CA, UNITED STATES  
Treuner, Kai, San Diego, CA, UNITED STATES  
Broadhead, Alex, San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): BrainCells, Inc., San Diego, CA, UNITED STATES (U.S.  
corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 20070049576	A1	20070301
APPLICATION INFO.:	US 2006-467527	A1	20060825 (11)

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2005-711846P	20050826 (60)
	US 2005-727127P	20051014 (60)
	US 2005-738133P	20051117 (60)
	US 2006-803826P	20060602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	

NUMBER OF CLAIMS: 26  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 15 Drawing Page(s)  
LINE COUNT: 4031

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2006:341526 USPATFULL  
TITLE: Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors  
INVENTOR(S): Thor, Karl Bruce, Cary, NC, UNITED STATES  
Ricca, Daniel J., Rougemont, NC, UNITED STATES  
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060293309	A1	20061228
APPLICATION INFO.:	US 2006-389887	A1	20060327 (11)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-666253P	20050328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	101	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4659	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention features compounds, for example, 5-HT.sub.3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT.sub.3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT.sub.3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT.sub.3 receptors can be lessened or reduced using the peripherally restricted compounds of the invention.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.  
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)  
RN 99487-26-0 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9  
 (MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



L8 ANSWER 9 OF 15 USPATFULL on STN  
 ACCESSION NUMBER: 2006:196249 USPATFULL  
 TITLE: New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine  
 INVENTOR(S): Cavalla, David, Cambridge, UNITED KINGDOM  
 Gristwood, Robert William, Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060167005	A1	20060727
APPLICATION INFO.:	US 2003-525532	A1	20030828 (10)
	WO 2003-GB3720		20030828
			20050725 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-20064	20020829
	GB 2003-16115	20030709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1-15	

LINE COUNT: 225

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 476148-82-0

(therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)


RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 476148-82-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H<sub>2</sub>O

L8 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:275228 USPATFULL

TITLE: 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine in the treatment of functional bowel disorder

INVENTOR(S): Cavalla, David, Cambridge, UNITED KINGDOM  
Gristwood, Robert William, Cambridge, UNITED KINGDOM

NUMBER KIND DATE

PATENT INFORMATION:	US 20050239792	A1	20051027	
APPLICATION INFO.:	US 2003-519594	A1	20030709	(10)
	WO 2003-GB2974		20030709	
			20041228	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-16027	20020710
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	160	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of functional bowel disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-26-0, MCI 225 476148-82-0  
(thienopyrimidine deriv.for treatment of pain)


RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)




RN 99487-26-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)



RN 476148-82-0 USPATFULL  
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H<sub>2</sub>O

L8 ANSWER 11 OF 15 USPATFULL on STN  
ACCESSION NUMBER: 2005:255664 USPATFULL  
TITLE: Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d)-pyrimidine for treating of urinary incontinence  
INVENTOR(S): Cavalla, David, Cambridge, UNITED KINGDOM  
Gristwood, Robert William, Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050222162	A1	20051006
	US 7220748	B2	20070522
APPLICATION INFO.:	US 2003-502827	A1	20030129 (10)
	WO 2003-GB374		20030129
			20040727 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-2265	20020131
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
LINE COUNT:	168	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or  
a salt thereof is useful for the treatment of urinary incontinence.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-26-0, MCI 225 476148-82-0

(piperazinylthienopyrimidine derivative for treating urinary incontinence)


RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 99487-26-0 USPATFULL


CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 476148-82-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H<sub>2</sub>O



L8 ANSWER 12 OF 15 USPATFULL on STN  
 ACCESSION NUMBER: 2004:321517 USPATFULL  
 TITLE: Method of treating nausea, vomiting  
 , retching or any combination thereof  
 INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
 Miller, Cheryl L., Natick, MA, UNITED STATES  
 Thor, Karl B., Morrisville, NC, UNITED STATES  
 PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254172	A1	20041216
	US 7094786	B2	20060822
APPLICATION INFO.:	US 2004-846979	A1	20040514 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING		


	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	CLM-01-70	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1783	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>3</sub> receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts  
 (method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



L8 ANSWER 13 OF 15 USPATFULL on STN  
 ACCESSION NUMBER: 2004:321516 USPATFULL  
 TITLE: Method of treating nausea, vomiting  
 , retching or any combination thereof  
 INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
 Miller, Cheryl L., Natick, MA, UNITED STATES  
 Thor, Karl B., Morrisville, NC, UNITED STATES  
 PATENT ASSIGNEE(S): Dynogen, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254171	A1	20041216
APPLICATION INFO.:	US 2004-846978	A1	20040514 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-757981, filed on 13 Jan 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492478P	20030804 (60)
	US 2003-440076P	20030113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	89	
EXEMPLARY CLAIM:	CLM-01-70	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1991	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>2B</sub> receptor antagonist activity and NorAdrenaline Reuptake

Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts

(method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)


RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
(CA INDEX NAME)



L8 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:190737 USPATFULL

TITLE: Method of treating nausea, vomiting  
, retching or any combination thereof

INVENTOR(S): Landau, Steven B., Wellesley, MA, UNITED STATES  
Miller, Cheryl L., Natick, MA, UNITED STATES  
Thor, Karl B., Morrisville, NC, UNITED STATES

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Boston, MA (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040147510	A1	20040729
APPLICATION INFO.:	US 2004-757981	A1	20040113 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2003-492478P 20030804 (60)  
 US 2003-440076P 20030113 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA  
 ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133  
 NUMBER OF CLAIMS: 70  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 3 Drawing Page(s)  
 LINE COUNT: 2041  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT<sub>3</sub> receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT<sub>3</sub> antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99487-25-9 99487-25-9D, salts

(method of treating nausea, vomiting, or retching by administering a 5-HT<sub>3</sub> receptor antagonist and noradrenaline reuptake inhibitor)


RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)



RN 99487-25-9 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)




L8 ANSWER 15 OF 15 USPATFULL on STN  
 ACCESSION NUMBER: 2004:64355 USPATFULL  
 TITLE: New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine  
 INVENTOR(S): Bardsley, Hazel Judith, Konstanz, GERMANY, FEDERAL REPUBLIC OF  
 Cavalla, David, Cambridge, UNITED KINGDOM  
 Gristwood, Robert William, Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040048874	A1	20040311
APPLICATION INFO.:	US 2003-617847	A1	20030710 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-GB2388, filed on 21 May 2002, UNKNOWN		


	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-112494	20020522
	GB 2002-16027	20020710
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	246	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 99487-25-9 99487-26-0, MCI-225 476148-82-0  
 (fluorophenylmethylpiperazinylthienopyrimidine for treatment of pain)  
 RN 99487-25-9 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-  
 (CA INDEX NAME)




RN 99487-26-0 USPATFULL  
 CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-,  
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 476148-82-0 USPATFULL

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H<sub>2</sub>O

=> d his

(FILE 'HOME' ENTERED AT 14:22:34 ON 07 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:22:41 ON 07 OCT 2008

L1 STRUCTURE UPLOADED

L2 0 S L1 EXA

L3 4 S L1 FUL

FILE 'USPATFULL' ENTERED AT 14:23:31 ON 07 OCT 2008

L4 39 S L3

L5 22 S L4 AND CANCER

L6 21 S L3 AND CHEMOTHERAPY

L7 7 S L3 AND CHEMOTHERAPEUTIC

L8 15 S L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

209.47

396.04

STN INTERNATIONAL LOGOFF AT 14:30:29 ON 07 OCT 2008